2.5 (2 votes) Over one million women are now using NuvaRing(R) - the award-winning, once-a-month contraceptive ring of Organon. Experts say this impressive number of satisfied users coupled with continuous month-to-month growth indicates that NuvaRing is increasingly being considered a mainstream contraceptive choice,trx rip trainer. NuvaRing is as reliable as the Pill but as a result of its unique once-a-month action provides a better fit with the busy lifestyles of women today. It also ends the daily concerns of forgetting the pill. It offers excellent cycle control, and minimizes women's hormone exposure compared to all other hormonal contraceptives, making it very well tolerated. "There is no doubt that the once-a-month action of NuvaRing is incredibly attractive to women, and increases users' confidence. On top of that, women are particularly interested in recent evidence showing that NuvaRing minimizes their hormone exposure compared to other methods. Low exposure has an immense appeal - women definitely view less as more when it comes to hormones," said Dr Rachel Arias, University of Southern California. "NuvaRing is increasingly being regarded as an important contraceptive option that in time could challenge the supremacy of the Pill." NuvaRing became available in the United States in July 2002 and is today available in 26 countries. Within Europe, uptake is increasing in all countries in which it is available with highest uptake in Finland, Spain and Germany. Uptake in the US - making up 50% of the one million - continues to increase and is expected to grow as more and more women know of NuvaRing. "Clinically, there is no doubt that NuvaRing is an excellent alternative to the Pill, and its use should be proposed among the best available methods of contraception to all women needing a safe contraceptive. Even so,weider x factor st, the idea of a vaginal contraceptive has taken women slightly by surprise," said Prof.ssa Chiara Benedetto, Head of University Division C of Obstetrics and Gynecology, University of Turin, Italy. "However, women are not only getting used to the idea but are now increasingly aware that NuvaRing's advantages are due to its unique route of administration." Toon Wilderbeek, President of Organon International: "There is a momentum growing around NuvaRing as a result of the numerous advantages it offers. No one method will ever suit all women but we believe that NuvaRing will continue to exceed the expectations of increasing numbers of women." NuvaRing was awarded the TIME award for Best Invention of the Year for health (2001), the best prescription drug of the year in Spain (2004), the therapeutic innovation of the year in gynecology in France (2004) and has consistently been voted gynecologists' choice of most innovative product in Germany. About Organon Organon - with shared head offices in Roseland, NJ, USA and Oss, The Netherlands - creates, manufactures and markets prescription medicines that improve the health and quality of human life,x factor supplement. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: gynecology, fertility, neuroscience and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel,trx pro pack. For further information, please visit Safe Harbor Statement* This report contains statements which address such key issues as Organon's growth strategy,trx bands, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the "Outlook," should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more complete discussion of the risk factors affecting our business please see the Akzo Nobel Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company's website www.akzonobel.com. * Pursuant to the U.S. Private Securities Litigation Reform Act 1995. View drug information on NuvaRing. BN ImmunoTherapeutics Starts Trials With New Breast Cancer V West ga health - HEALTH, BEAUTY & FITNESS